Abstract
Essential hypertension is a major factor for myocardial infarction, heart failure and kidney failure. Dopamine plays an important role in the pathogenesis of hypertension by regulating epithelial sodium transport and vasodilatation directly or indirectly with other hormones and humoral factors, such as reactive oxygen species and the renin-angiotensin system. Dopamine receptors are classified into five subtypes based on their structure and pharmacology. Among those dopamine receptor subtypes, D1 receptor is the most important one, during conditions of moderate sodium intake, more than 50% of renal sodium excretion is regulated by D1-like receptors. Decreased renal dopamine production and/or impaired D1 receptor function have been reported in hypertension. Disruption of D1 receptor results in hypertension. In this paper, we review the mechanisms by which hypertension develops when D1 receptor function is perturbed. We also discuss possible new approaches developing anti-hypertensive medicine by increasing renal dopamine production, enhancing D1 receptor function, or modifying its interactions with other blood pressure-regulating systems.
Keywords: Essential hypertension, D1 dopamine receptor, G protein-coupled receptor kinase type 4, protein phosphotase 2A, endocytosis, desensitization, sodium excretion, vasorelaxation
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: A New Approach for Treatment of Hypertension: Modifying D1 Dopamine Receptor Function
Volume: 4 Issue: 4
Author(s): Chunyu Zeng, Robin A. Felder and Pedro A. Jose
Affiliation:
Keywords: Essential hypertension, D1 dopamine receptor, G protein-coupled receptor kinase type 4, protein phosphotase 2A, endocytosis, desensitization, sodium excretion, vasorelaxation
Abstract: Essential hypertension is a major factor for myocardial infarction, heart failure and kidney failure. Dopamine plays an important role in the pathogenesis of hypertension by regulating epithelial sodium transport and vasodilatation directly or indirectly with other hormones and humoral factors, such as reactive oxygen species and the renin-angiotensin system. Dopamine receptors are classified into five subtypes based on their structure and pharmacology. Among those dopamine receptor subtypes, D1 receptor is the most important one, during conditions of moderate sodium intake, more than 50% of renal sodium excretion is regulated by D1-like receptors. Decreased renal dopamine production and/or impaired D1 receptor function have been reported in hypertension. Disruption of D1 receptor results in hypertension. In this paper, we review the mechanisms by which hypertension develops when D1 receptor function is perturbed. We also discuss possible new approaches developing anti-hypertensive medicine by increasing renal dopamine production, enhancing D1 receptor function, or modifying its interactions with other blood pressure-regulating systems.
Export Options
About this article
Cite this article as:
Zeng Chunyu, Felder A. Robin and Jose A. Pedro, A New Approach for Treatment of Hypertension: Modifying D1 Dopamine Receptor Function, Cardiovascular & Hematological Agents in Medicinal Chemistry 2006; 4 (4) . https://dx.doi.org/10.2174/187152506778520727
DOI https://dx.doi.org/10.2174/187152506778520727 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of ARBs in the Blood Hypertension Therapy and Prevention of Cardiovascular Events
Current Drug Targets Hypoxia as an Initiator of Neuroinflammation: Microglial Connections
Current Neuropharmacology Vitamin D and Metabolic Syndrome: Is There a Link?
Current Pharmaceutical Design The Protective Effects of Natural Products on Blood-Brain Barrier Breakdown
Current Medicinal Chemistry Adrenomedullin in Cardiovascular Disease: A Useful Biomarker, its Pathological Roles and Therapeutic Application
Current Protein & Peptide Science Mitochondria, Cellular Stress Resistance, Somatic Cell Depletion and Lifespan
Current Aging Science Therapeutic Interventions to Renin-Angiotensin-Aldosterone System, and Vascular Redox State
Recent Patents on Cardiovascular Drug Discovery Hypertension and Endothelial Dysfunction: Therapeutic Approach
Current Vascular Pharmacology Iatrogenic Right Atrial Thrombus Complicated by Pulmonary Embolism: Management and Outcomes
Current Cardiology Reviews Method Development & Validation of LCMS/MS for Atorvastatin and Olmesartan in Human Plasma to Trace Drug Interaction of Formulation
Current Pharmaceutical Analysis Inhibitors of Leucine-Rich Repeat Kinase 2 (LRRK2): Progress and Promise for the Treatment of Parkinson’s Disease
Current Topics in Medicinal Chemistry Sphingolipids in Cell Signaling: Their Function as Receptor Ligands, Second Messengers, and Raft Constituents
Current Immunology Reviews (Discontinued) A Focus on Pharmacological Management of Catecholaminergic Polymorphic Ventricular Tachycardia
Mini-Reviews in Medicinal Chemistry Targeting Vascular Niche by Parathyroid Hormone
Current Medicinal Chemistry Data-driven Approach to Detect and Predict Adverse Drug Reactions
Current Pharmaceutical Design NAD<sup>+</sup>/NADH Metabolism and NAD<sup>+</sup>-Dependent Enzymes in Cell Death and Ischemic Brain Injury: Current Advances and Therapeutic Implications
Current Medicinal Chemistry Systemic Adverse Drug Reactions Secondary to Anti-VEGF Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration
Current Vascular Pharmacology General Anesthetics in Brain Injury: Friends or Foes?
Current Pharmaceutical Design Impact of DNA Vector Topology on Non-Viral Gene Therapeutic Safety and Efficacy
Current Gene Therapy Goal Directed Fluid Therapy
Current Pharmaceutical Design